By Anuja Vaidya March 02, 2023 – The adoption of remote patient monitoring (RPM) has skyrocketed, with RPM claim volume increasing by 1,294 percent from January 2019 to November 2022, according to…
Continue Reading
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
By Shania Kennedy
February 28, 2023 – New Jersey-based AtlantiCare is deploying pre-operative artificial intelligence (AI) assessment tools and robotic bronchoscopy techniques to support early lung cancer diagnosis and treatment.
The health system will leverage…
Eko SENSORA Cardiac Disease Detection Platform on tablet featuring 3M Littmann CORE Digital Stethoscope
“We’ve called it Shazam for heartbeats. You know Shazam, the music identification app that helps you figure out what song is…
Steve House is managing director of Baker Tilly US of Chicago, IL.
Tell me about yourself and the company.
I realized the other day that I have entered my 40th year in healthcare….
The underdiagnosed and poor management of COPD exacerbations represents a missed opportunity to prevent patient deterioration through proactive treatment approaches.
Chronic obstructive pulmonary disorder (COPD) remains a leading cause of poor health and mortality the…
Dr. Ty Vachon, CEO & Co-Founder at Oatmeal HealthToday, cancer is the second leading cause of death in the United States. Sadly, cancer disparities exist, with racial/ethnic minority, low-income, and uninsured populations suffering the greatest burden. That’s why routine cancer screening is critical to addressing cancer disparities as they have the potential to greatly reduce both incidence and mortality rates. To address this, Federally qualified health centers (FQHCs) are funded by the Health Resources and Services Administration to provide preventive and primary healthcare services, including cancer screening, to the nation’s most vulnerable populations We recently sat down with Oatmeal Health’s Co-Founder and…
Continue Reading
To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one in five deaths in 2020 in theUnited States.
Even minimally invasive pulmonary artery banding — a surgical technique that has been in use since Harry Truman was president — requires access to the chest cavity. A new treatment under development by HeartPoint Global seeks to provide a minimally invasive alternative to current treatments for pulmonary arterial hypertension associated with Congenital Heart Disease.A device delivered through the leg would cost only…
A slew of biotech companies are pursuing research that could overcome limitations of current cell therapies. Startup creator Replay has a new subsidiary pushing toward the front of the pack with a therapeutic candidate on track to start its first human test this summer—about one year after Replay emerged from stealth. It owes this rapid progress to a cell therapy pioneer’s technology that has already been de-risked by a big pharmaceutical company.
Replay calls itself a genome writing company. With operations split between San Diego and London, the private equity-backed business launched last July with $55 million and a suite of technologies…
G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…
